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AAV-mediated in vivo knockdown of luciferase using
combinatorial RNAi and U1i
A Koornneef1, R van Logtenstein1, E Timmermans1, L Pisas1, B Blits1, X Abad2,3, P Fortes2, H Petry1,
P Konstantinova1 and T Ritsema1
RNA interference (RNAi) has been successfully employed for speciﬁc inhibition of gene expression; however, safety and
delivery of RNAi remain critical issues. We investigated the combinatorial use of RNAi and U1 interference (U1i). U1i is a
gene-silencing technique that acts on the pre-mRNA by preventing polyadenylation. RNAi and U1i have distinct mechanisms
of action in different cellular compartments and their combined effect allows usage of minimal doses, thereby avoiding toxicity
while retaining high target inhibition. As a proof of concept, we investigated knockdown of the ﬁreﬂy luciferase reporter gene
by combinatorial use of RNAi and U1i, and evaluated their inhibitory potential both in vitro and in vivo. Co-transfection of RNAi
and U1i constructs showed additive reduction of luciferase expression up to 95% in vitro. We attained similar knockdown when
RNAi and U1i constructs were hydrodynamically transfected into murine liver, demonstrating for the ﬁrst time successful in vivo
application of U1i. Moreover, we demonstrated long-term gene silencing by AAV-mediated transduction of murine muscle with
RNAi/U1i constructs targeting ﬁreﬂy luciferase. In conclusion, these results provide a proof of principle for the combinatorial
use of RNAi and U1i to enhance target gene knockdown in vivo.
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INTRODUCTION
Gene silencing through RNA interference (RNAi) holds great potential
for the treatment of various diseases, such as cancer, neurodegenera-
tive disorders and viral infections. Since its basic discovery, RNAi
research has advanced rapidly and has already made its way to the
clinic, with phase I and II clinical trials under way.1,2 RNAi is an
evolutionarily conserved sequence-speciﬁc post-transcriptional gene
silencing mechanism in eukaryotes that results in the degradation of
mRNA and subsequently in decrease of protein synthesis.3,4 Small
double-stranded RNA molecules with perfect sequence complemen-
tarity to the target mRNA are processed by Dicer, rendering a mature
small interfering RNA (siRNA) to interact with the cytosolic multi-
protein RNA-induced silencing complex (RISC). The RISC-incorpo-
rated siRNA binds to a complementary mRNA sequence, which leads
to cleavage of the target mRNA, followed by degradation through
cellular RNases.5,6
RNAi delivery methods employ both synthetic small interfering
RNAs (siRNAs) that can be added to the cell, and DNA-based vectors
that encode short hairpin RNAs (shRNAs), which upon expression
are processed intracellularly to siRNAs.6 Expression of these shRNAs
is typically regulated by constitutive strong polymerase III (pol III)
promoters (H1 or U6), but their expression can also be made
tissue speciﬁc or inducible, depending on the choice of promoter.7,8
Speciﬁcity can be increased by encapsidation of the shRNA into a viral
vector with speciﬁc tissue tropism. In addition, viral vector-mediated
delivery of shRNA-encoding constructs has the advantage of long-term
RNAi upon single administration.6,9 Recombinant adeno-associated
(AAV) viral vectors are excellent vehicles for RNAi-based gene therapy
as they allow efﬁcient, safe, long-term gene delivery in a wide range of
tissues. AAV is a single-stranded DNA virus with a 4.7-kb genome
ﬂanked by inverted terminal repeats (ITRs), which are cis-acting
elements needed for AAV packaging and DNA replication. Recombi-
nant AAV is devoid of all viral genes except the ITR sequences and is
considered a safe vector as it lacks pathogenicity and persists mainly
episomally, rather than integrating in the host genome. AAV vectors
have great versatility and delivery potential through the availability of
multiple serotypes, which can be expanded further by pseudotyping
and capsid modiﬁcation.10,11
Despite successful demonstration of RNAi in vivo and initiation of
clinical trials using RNAi-based therapeutics, safety and delivery of
RNAi remain critical issues.1,12 Adverse immune responses, off-target
effects and saturation of the cellular RNAi processing machinery have
been reported, which demonstrates the need for optimization of
therapeutic gene-silencing technologies.13–15 For gene therapy-based
RNAi, this could be achieved by controlling intracellular shRNA
expression levels, which however requires cumbersome optimization.
An alternative approach is to combine RNAi with gene-silencing
technologies with a different mode of action that do not use the
same processing pathway as RNAi.
U1 interference (U1i) is a novel post-transcriptional gene-silencing
method that inhibits polyadenylation and maturation of pre-mRNAs.
The technology is based on a modiﬁed U1 small nuclear ribonucleo-
protein particle (snRNP). Mammalian wild-type U1 snRNP consists
of a 164-nt U1 small nuclear RNA (snRNA) bound by 10 polypeptides,
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www.nature.com/gtone among which is U1-70K, and it functions as part of the
spliceosome in pre-mRNA splicing by hybridizing to the 5¢ splice
sites of introns using the 10 nucleotides at its 5¢ end for recognition.
In addition, U1 snRNP has an alternative role in the inhibition of gene
expression by binding the 3¢ untranslated region of papillomaviruses
and certain mammalian genes.16–18 Upon base-pairing of the 10
nucleotides at the 5¢ end of U1 snRNA to a target sequence in the
3¢ untranslated region, polyadenylation of the target pre-mRNA is
inhibited through a direct interaction of the U1-70K protein subunit
of U1 snRNP with poly(A) polymerase.19 Inhibition of polyadenyla-
tion prevents maturation of pre-mRNA, which is subsequently
degraded in the nucleus. By using this naturally occurring mechanism,
a gene-speciﬁc silencing method based on inhibition of pre-mRNA
polyadenylation and maturation is established. Speciﬁc modiﬁcation
of the 10 nucleotides at the 5¢ end of U1 snRNA leads to base-pairing
with the 3¢ terminal exon of a desired target gene, resulting in the
inhibition of polyadenylation, prevention of maturation, and ﬁnally in
targeting of pre-mRNA for degradation. This approach has been
successfully employed in vitro upon transient and stable delivery of
DNA-encoding modiﬁed U1 snRNA to various cell lines, resulting in
the repression of reporter genes as well as endogenous genes.20–26
Combining RNAi and U1i gene silencing yields more efﬁcient
knockdown of gene expression, as these methods have distinct
mechanisms of action in different cellular compartments.27 RNAi
takes place in the cytosol and involves cleavage of mRNA, whereas
U1i is effective in the nucleus and functions through prevention of
pre-mRNA maturation.6,19 A combinatorial approach allows usage of
minimal doses of individual components (RNAi and U1i), thereby
reducing the chances of toxicity, such as saturation of cellular RNAi
pathways. Simultaneous application of siRNA and U1i molecules that
target the same gene has been shown to enhance silencing in vitro.18
Furthermore, Abad et al.27 recently demonstrated synergistic enhance-
ment of reporter and endogenous gene silencing by the combined
action of RNAi with U1i. However, the effectiveness of these combined
silencing methods has yet to be demonstrated in vivo.
Here, we employed the ﬁreﬂy luciferase reporter gene to quantify
gene silencing by the combined action of RNAi and U1i. First, shRNA
and U1i plasmids targeting ﬁreﬂy luciferase were co-transfected
in vitro in HEK293T cells. Second, the in vivo activity of co-transfected
shRNA and U1i plasmids was assessed in murine liver using hydro-
dynamic transfection. Finally, AAV-mediated transduction of murine
muscle was employed to demonstrate stable in vivo suppression of
luciferase expression by combinatorial RNAi and U1i. We show that
co-transfection of RNAi with U1i constructs has an additive effect on
reporter gene knockdown both in vitro and in vivo, compared with
transfection with either effector alone. In addition, AAV-delivered
RNAi and U1i result in prolonged inhibition of luciferase expression
in murine muscle. Overall, these data illustrate the effectiveness of
RNAi and U1i gene-silencing methods both in vitro and in vivo, which
is of interest for the development of therapeutic applications.
RESULTS
Screening of shRNA and U1i constructs targeting luciferase
To evaluate the inhibitory effect of RNAi and U1i on gene expression,
we chose the ﬁreﬂy luciferase reporter as a target gene. Knockdown of
luciferase was assayed by transfecting shRNA constructs targeting
ﬁreﬂy luciferase together with ﬁreﬂy and renilla luciferase reporter
plasmids. The ratio of ﬁreﬂy and renilla luciferase signal was used to
calculate relative luciferase activity. shLuc1 was highly effective and
showed a dose-dependent luciferase knockdown up to approximately
85%, whereas shLuc2 was ineffective (Figure 1a).
Figure 1 In vitro knockdown of luciferase by shRNA and U1i constructs.
(a) Increasing amounts (1–250ng) of shRNA constructs targeting ﬁreﬂy
luciferase (shLuc1 and shLuc2) were co-transfected with 2.5ng ﬁreﬂy
luciferase and 0.5ng renilla luciferase plasmid in 96-well plates containing
approximately 2.5 104 HEK293T cells. The total amount of transfected DNA
was kept constant by adding the pSuper cloning vector. At 2 days after
transfection, cells were lysed and ﬁreﬂy and renilla luciferase signals were
measured. Relative luciferase activity was calculated as the ratio of ﬁreﬂy
and renilla luciferase and plotted relative to the 100% control transfected
with 250ng pSuper. shLuc1 signiﬁcantly reduced luciferase by 85%,
whereas shLuc2 was inactive. Control shRNA plasmids were shGFP and
shApoB. (b) Co-transfection of 200ng U1i constructs targeting ﬁreﬂy luciferase
(L1-L8) with ﬁreﬂy luciferase and renilla luciferase plasmid. Cells transfected
with 200ng control plasmid U1C were set at 100%. L4 and L5 mildly reduced
luciferase expression by 30 and 40%, respectively, compared with U1C. (c)C o -
transfection of 100ng L4 and 100ng L5 signiﬁcantly improved luciferase
inhibition, compared with transfection with 200ng L4 or L5 alone (Po0.05).
Data are presented as mean of three technical replicates±s.d.
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Gene TherapyEight U1 interference (U1i) constructs targeting ﬁreﬂy luciferase
(L1–L8) were designed and screened for knockdown of ﬁreﬂy lucifer-
ase. Co-transfection of L1–L8 constructs with ﬁreﬂy and renilla
luciferase reporters demonstrated a mild inhibitory effect of two out
of the eight U1i constructs (Figure 1b). L4 and L5 reduced luciferase
expression by 30 and 40%, respectively. We proceeded to test the
combined effect of the two mildly effective U1i constructs with other
U1i constructs in order to screen for improved efﬁcacy (Supplemen-
tary Table 1). The strongest decrease in luciferase expression was
observed by the combination of L4 with L5 and reached around 80%
(Supplementary Table 1 and Figure 1c). Next, a bicistronic expression
vector was cloned that simultaneously expressed L4 and L5 from one
backbone. Transfection with this double U1i plasmid L4/L5 was
equally effective in suppressing luciferase activity as co-transfection
with L4 and L5 single plasmids, indicating that there is efﬁcient
expression of both effectors from one backbone (data not shown).
Thus, although the single U1i constructs tested were only mildly
effective on their own, they can be combined to reduce luciferase
expression to a similar level as the shLuc1 construct.
Co-expression of shRNA and U1i enhances luciferase knockdown
in vitro
Combining RNAi and U1i gene silencing allows more efﬁcient knock-
down of gene expression as they have distinct mechanisms of action in
different cellular compartments. Therefore, we co-transfected shLuc1
together with the most effective U1i constructs L4 and L5. Transfec-
tion of L4 or L5 combined with control shApoB led to a mild decrease
in luciferase expression of approximately 30 and 40%, respectively,
comparable to the single U1i constructs (Figures 1b and 2a). Expres-
sion of the control plasmid shApoB together with the combined
expression of L4 and L5 or the bicistronic L4/L5 construct suppressed
luciferase even more (Figure 2a). When shLuc1 was co-transfected
with control U1C, an 86% reduction in luciferase expression was
observed, similar to the inhibition shown with shLuc1 alone (Figures
1a, 2a and b). We were able to signiﬁcantly enhance luciferase
knockdown when the three luciferase-targeting constructs, shLuc1,
L4, and L5, were combined and when shLuc1 was combined with the
bicistronic L4/L5 construct, resulting in a 95% reduction in luciferase
activity (Figure 2b). The additive effect of L4 and L5 was shown for
several shLuc1 concentrations (Supplementary Figure 1). Hence,
co-expression of RNAi and U1i enhances target gene knockdown
in vitro, consistent with previous data.27
Transient in vivo delivery of shRNA and U1i enhances luciferase
knockdown in murine liver
The in vivo silencing activity of RNAi and U1i was evaluated in
murine liver by hydrodynamic co-transfection of shLuc1 and bicis-
tronic L4/L5 plasmids. shLuc1 was mixed with L4/L5 and injected
together with the ﬁreﬂy luciferase reporter plasmid and a construct
expressing secreted alkaline phosphatase (SEAP). Plasma measure-
ments of co-injected SEAP plasmid served to normalize for transfec-
tion efﬁciency. In vivo delivery of shLuc1 and L4/L5 plasmids resulted
in 85% knockdown of relative luciferase expression at two days
post-transfection, which was comparable to luciferase knockdown
observed in vitro (Figures 2b and 3). In addition, we observed
intermediate suppressive effects of L4/L5 alone (25% in combination
with control shApoB) and of shLuc1 alone (61% in combination with
control H1/H4) (Figure 3). These results demonstrate the feasibility
of in vivo suppression of a target gene by the combined action of
RNAi and U1i.
Simultaneous expression of shRNA and bicistronic U1i constructs
from a single backbone inhibits luciferase expression in vitro
In order to develop therapeutic applications using RNAi and U1i,
durable expression of these gene-silencing mechanisms has to be
established. For long-term expression, AAV vectors are excellent
delivery vehicles that are capable of transducing a wide range of
tissues with high efﬁciency. Therefore, we proceeded to express shLuc1
and L4/L5 from an AAV backbone. The U1i bicistronic construct
L4/L5 was cloned together with shLuc1 in a pro-AAV cloning vector
(LL) (Supplementary Figure 2). Each individual effector was expressed
from their own promoter and termination sequences. Three additional
Figure 2 Combination of RNAi and U1i increases luciferase knockdown in vitro.( a) Co-transfection of 50ng control shApoB construct or 50ng shLuc1
construct with 200ng (or 100+100ng) U1i plasmid and ﬁreﬂy luciferase and renilla luciferase plasmid. Transfections and analysis were carried out as
described in Figure 1a. Cells transfected with a combination of 50ng shApoB and 200ng U1C were set at 100%. Co-transfection of shApoB with L4 and L5
or L4/L5 signiﬁcantly reduced luciferase activity by B65% compared with the 100% control (Po0.05). Transfection of shLuc with U1C resulted in a
signiﬁcant 86% knockdown (Po0.001). (b) Co-transfection of 50ng shLuc1 construct with 200ng (or 100+100ng) U1i plasmid and ﬁreﬂy luciferase and
renilla luciferase. Note the different scales on the y axes in (a, b). Co-transfection of shLuc1 with L4 and L5 maximally reduced luciferase expression by
95%. Control U1i constructs were U1C, and H1 and H4 that target the human huntingtin sequence. Luciferase activity after co-transfection of shLuc1 with
L4 and L5 or L4/L5 was signiﬁcantly different from co-transfection of shLuc1 with U1C (Po0.05), and from co-transfection of shLuc1 with H1 and H4
(Po0.001) or H1/H4 (Po0.05). Data are presented as mean of three independent experiments +s.d., analyzed using factor correction.36
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U1i H1/H4 (AH), a second that expressed anti-luciferase U1i L4/L5
and control shApoB (AL), and a third that expressed anti-luciferase
shLuc1 and control U1i H1/H4 (LH). Upon transfection of HEK293T
cells, qPCR analysis conﬁrmed that all four shRNA/U1i constructs
expressed recombinant U1 snRNA (Supplementary Figure 3a).
Furthermore, their expression did not affect cell viability, as deter-
mined by the MTT toxicity assay (Supplementary Figure 3b). To assess
the in vitro inhibitory potential of the shRNA/U1i co-expression
constructs, increasing amounts of plasmid were co-transfected
together with ﬁreﬂy and renilla reporters. All luciferase-targeting
constructs (LH, AL, LL) signiﬁcantly suppressed luciferase activity
compared with the control AH (Figure 4). Of these, the RNAi and U1i
double inhibitory construct (LL) was most effective and reduced
luciferase expression by 85%. Although the combined effect of
shLuc1 and L4/L5 (LL) appeared to be stronger than the effect of
shLuc1 alone (LH), this effect was not signiﬁcant. This may be due to
the fact that all three constructs were expressed from one vector,
thereby missing the ability to differentially dose the inhibitory con-
structs for optimal effect.
AAV-mediated knockdown of luciferase using RNAi and U1i in
murine muscle
Having established the in vitro efﬁcacy of the shRNA/U1i co-expres-
sion constructs, we proceeded to investigate long-term in vivo sup-
pression of luciferase in murine muscle by employing AAV serotype 1
viral vectors to deliver shLuc1 and L4/L5. AAV1-expressing luciferase
reporter (AAV-Luc) was co-injected intramuscularly with the AAV
viral vectors encoding the shRNA/U1i co-expression constructs AAV-
AH (shApoB and H1/H4), AAV-AL (shApoB and L4/L5), AAV-LH
(shLuc1 and H1/H4), or AAV-LL (shLuc1 and L4/L5). All AAV-
shRNA/U1i vectors co-expressed the GFP reporter gene, and full
muscle transduction was demonstrated by monitoring GFP expression
at 8 weeks post-injection (data not shown). Recombinant U1 snRNA
expression was shown for all four AAV-shRNA/U1i vectors in trans-
duced muscle at 8 weeks post-transduction (Supplementary Figure 4).
In addition, the absence of muscle damage was demonstrated by
creatine phosphokinase (CPK) assay and by hematoxylin and eosin
(H&E) staining of frozen muscle sections (data not shown).
Luciferase expression was monitored at 1, 2, 3, 4, 6, and 8 weeks
post-transduction (Figure 5). Overall, luciferase expression increased
over time during the ﬁrst weeks post-transduction with AAV-Luc and
AAV-shRNA/U1i, and reached a relatively stable level at 4 weeks,
characteristic of AAV expression kinetics.28 Transduction with AAV-
shRNA/U1i targeting ﬁreﬂy luciferase (AAV-LL) reduced luciferase
expression signiﬁcantly by 25–40% compared with the control vector
AAV-AH (Figure 5). This effect was already observed at 1 week post-
transduction and remained stable throughout the course of the
experiment, demonstrating the effectiveness and stability of luciferase
knockdown by combined RNAi and U1i expression in vivo.O v e r a l l ,
luciferase suppression in vivo was lower than observed in vitro;t h e
maximum inhibitory effect of shLuc and L4/L5 (LL) was 40% in vivo,
versus 85% in vitro (Figures 4 and 5). Moreover, we could not observe
a signiﬁcant effect of the U1i constructs alone (AAV-AL), or of the
shRNA construct alone (AAV-LH). The fact that we did not observe an
intermediate inhibitory effect of these constructs may reﬂect an overall
lower knockdown in vivo compared with the effect measured in vitro
(Figures 4 and 5). In conclusion, we demonstrated long-term stable
transduction of murine muscle using AAV delivery vectors and
observed sustained in vivo knockdown of a luciferase reporter by
the combined action of RNAi and U1i.
DISCUSSION
Delivery and safety of the therapeutic molecules remain major
challenges in the RNAi ﬁeld. These safety concerns involve unwanted
activation of the immune response, off-targeting effects, and
Figure 3 Hydrodynamic delivery of shRNA and U1i constructs to murine
liver inhibits luciferase activity in vivo. Mice were hydrodynamically co-
transfected with 10mg shRNA (shLuc1 or control shApoB) and 40mgd o u b l e
U1i (L4/L5 or control H1/H4) plasmid and with 2mg ﬁreﬂy luciferase
reporter and 0.5mg secreted alkaline phophatase (SEAP) plasmid. Both the
ﬁreﬂy luciferase and SEAP reporter gene were expressed under control of the
liver-speciﬁc AAT promoter, as hydrodynamically delivered plasmid DNA
localizes mainly to the liver. Two days after transfection, bioluminescence
was measured in the IVIS, and luciferase signal was calculated relative to
plasma SEAP levels. Murine liver co-transfected with control constructs
shApoB and H1/H4 was set at 100%. Co-transfection of shLuc1 with L4/L5
maximally reduced luciferase activity by 84%. However, luciferase
knockdown was not signiﬁcantly different between treatments. Data are
presented as mean (n¼4–8)±s.e.
Figure 4 Co-expression of RNAi and U1i from one vector backbone
suppresses luciferase activity in vitro. Increasing amounts (25–250ng) of
shRNA/U1i plasmid expressing both shRNA and double U1i constructs were
co-transfected with ﬁreﬂy luciferase and renilla luciferase plasmid and
analyzed as described in Figure 1a. The total amount of transfected DNA
was kept constant by adding the pro-AAV cloning vector. Cells transfected
with 250ng pro-AAV vector were set at 100%. The control vector AH
expressed shApoB and double H1/H4. The U1i vector AL expressed shApoB
and double L4/L5. The shRNA vector LH expressed shLuc1 and double
H1/H4. The shRNA and U1i combination vector LL expressed shLuc1 and
double L4/L5. AL, LH, and LL signiﬁcantly reduced luciferase activity
compared with the AH control vector (Po0.001) and LL was most effective
and led to 85% luciferase knockdown. Data are presented as mean of three
independent experiments±s.d., analyzed using factor correction.36
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shRNA.13–15 To minimize the risk of these unwanted effects while
retaining high target inhibition, we investigated the combined action
of RNAi and U1i, two gene-silencing mechanisms with different
modes of action. As a proof of concept, we studied the inhibitory
effect of RNAi and U1i on luciferase reporter expression, and
demonstrated increased luciferase knockdown in vitro by shRNA
and U1i transfection as well as prolonged suppression in vivo using
AAV-delivered shRNA/U1i expression cassettes.
Combinatorial RNAi strategies that aim to avert viral resistance
(for example, of HIV) by triggering RNAi against multiple targets
have been previously developed. These studies often involve expression
of several shRNA molecules, which is expected to proportionally
increase the toxicity and off-targeting risk associated with mono-
RNAi treatments.29 To circumvent these problems, Hemmings-
Mieszczak et al.30 combined siRNAs with antisense oligonucleotides
and observed synergistic knockdown effects in cultured cells. Similarly,
Jarczak et al.31 mixed shRNAs with hammerhead ribozymes, which
overall increased target gene inhibition. The in vivo efﬁcacy of these
combinatorial approaches nevertheless remains to be demonstrated.
Combinatorial use of RNAi with U1i in cell lines has been described
previously for both reporter and endogenous genes, and was shown to
yield synergistic suppressive effects on target gene expression.18,27 We
observed a similar effect when transfecting shLuc1 with two U1i
constructs L4 and L5, which resulted in 95% inhibition of luciferase
activity. Of the individual components, shLuc1 was most effective,
yielding B85% knockdown, and the combination of L4 with L5
resulted in B70–80% luciferase inhibition. Previously, increased target
knockdown was observed when several U1i constructs were expressed
that recognized multiple targets, or when a U1i construct was
expressed that recognized repeat regions in the 3¢ terminal exon of a
target gene.22 However, the U1i constructs tested here were only
mildly effective on their own. When screening the eight U1i constructs
(L1–L8), we observed not only inhibition of luciferase expression, but
even stimulatory effects on luciferase expression by two of the U1i
constructs, L3 and L6; the cause for this is currently unclear. Successful
design of U1i constructs seems to depend most strongly on the
accessibility of the secondary structure of the target region and may
have been suboptimal.26 In addition, Abad et al.27 observed a milder
inhibitory effect of their U1i construct when the target sequence was
expressed within the ﬁreﬂy luciferase plasmid, compared with expres-
sion in the previously used renilla luciferase construct, and suggested
that this decrease in efﬁcacy might reﬂect the effect of neighboring
sequences.
To prove the feasibility of combinatorial RNAi and U1i, we aimed at
demonstrating luciferase knockdown in vivo upon delivery of shRNA
and U1i constructs in a murine model. U1i has not been established
in animal models yet, and this is considered an important step in
the development of this gene-silencing mechanism as a therapy.32
Two approaches were employed, each targeting a different organ;
transient luciferase knockdown by plasmid delivery of shLuc1 and
L4/L5 to the liver, and their long-term effect by AAV-mediated
expression in the muscle. A strong reduction in luciferase expression
was shown upon hydrodynamic transfection of murine liver with
shLuc1 and the bicistronic L4/L5 construct, and intermediate inhibi-
tory effects were observed after transfection with shLuc1 and L4/L5
alone. These results matched the observations in cell cultures, and
prompted us to investigate the long-term silencing ability of combi-
natorial RNAi and U1i in murine muscle. AAV-mediated transduction
of murine muscle is expected to yield high-level long-term expression,
and indeed, the AAV-delivered vector co-expressing shLuc1 and
double L4/L5 signiﬁcantly reduced luciferase expression compared
with the control AAV vector. However, the effect was relatively mild
compared with in vitro observations. In addition, no signiﬁcant
luciferase suppression by shLuc1 or L4/L5 alone was measured.
Possibly, the lower efﬁcacy is due to the fact that all three effectors
were expressed from one backbone, which might result in promoter
interference when expressed in vivo. Alternatively, co-injection of AAV-
Luc with AAV-shRNA/U1i viral vectors may have resulted in trans-
duced cells that express luciferase, but not the shRNA/U1i inhibitors,
or vice versa. This would lower the overall efﬁcacy of luciferase
knockdown. Nevertheless, the inhibitory effect of AAV-delivered
shLuc and L4/L5 lasted throughout the course of the 8-week experi-
ment and failed to show any obvious signs of toxicity, as determined by
CPK assay and H&E staining. Thus, although the AAV vectors and
possibly the AAV dose need to be optimized, we were able to show a
proof of principle for the in vivo use of combinatorial RNAi and U1i.
Future research is needed to optimize the inhibitory potential of
combined RNAi and U1i in vivo when delivered with AAV, and
furthermore requires investigation into the potential toxic or off-
target effects of U1i gene silencing. With respect to the latter, U1i has
the advantage that it only works in the 3¢ terminal exon of a target
gene, and that secondary structures occlude target sequences.22,26
Indeed, Goraczniak et al.18 reported comparable limited off-target
effects by siRNA and U1 snRNA-mediated gene silencing in micro-
array analyses. In addition, the naturally occurring U1 snRNP is
highly abundant, with about one million copies present in a typical
mammalian nucleus, and therefore overexpression of modiﬁed
U1i constructs is not expected to interfere with the overall splicing
machinery.33 Furthermore, stable expression of U1i constructs has
been demonstrated in stably transduced cell lines, thus indicating the
low toxicity of this technique.22 Finally, optimization and validation of
U1i design rules should improve target gene knockdown, which allows
use of lower dose of U1i constructs, thus aiding in improving the
safety of the U1i gene-silencing technique. In conclusion, this study
shows for the ﬁrst time the in vivo application of U1i and furthermore
demonstrates the in vivo efﬁcacy of combinatorial RNAi and U1i.
Figure 5 AAV-mediated in vivo knockdown of luciferase using RNAi and U1i.
Murine muscle was co-transduced with 1 1010 gc AAV-Luc and 4.5 1010
gc AAV-shRNA/U1i per hind limb. The gastrocnemic and adductor muscles
of both hind limbs were injected. Six mice per treatment were injected,
resulting in n¼12. Luciferase expression was measured in the IVIS at 1, 2,
3, 4, 6, and 8 weeks post-transduction. The control vector AAV-AH
expressed shApoB and double H1/H4. The U1i vector AAV-AL expressed
shApoB and double L4/L5. The shRNA vector AAV-LH expressed shLuc1 and
double H1/H4. The shRNA and U1i combination vector AAV-LL expressed
shLuc1 and double L4/L5, and this viral vector signiﬁcantly reduced
luciferase expression on average by 25% during the course of the
experiment (Po0.05). Data are presented as mean (n¼12)±s.e.
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DNA constructs
shRNA constructs were made by annealing complementary oligonucleo-
tides and ligating them into the BglII and XhoI site of the pSuper vector
(OligoEngine, Seattle, WA, USA). shRNAs expressed from this plasmid are
transcribed from a H1 promoter. Two shRNAs were designed that target ﬁreﬂy
luciferase (shLuc1 and shLuc2) and two control shRNAs were made that target
GFP or human ApoB (shGFP and shApoB). The sequences of the oligonucleo-
tides used in this study are listed in Supplementary Table 2. Eight U1i
constructs were designed that target ﬁreﬂy luciferase (L1–L8), and three control
U1i constructs were made that target human huntingtin (H1 and H4) or
express the wild-type U1 sequence (U1C).22 The locations of each shRNA and
U1i luciferase target sequence are shown in Supplementary Figure 5. U1i
constructs were made by annealing complementary oligonucleotides and
ligating them into the BglII and BclI sites of a pGEM-3Zf+ plasmid (Promega,
Madison, WI, USA) encoding the U1 snRNA sequence including promoter and
termination sequences.26 Bicistronic U1i constructs encoding L4/L5 and H1/H4
were made by digestion of L4 and H4 with XbaI, followed by blunting of these
digested plasmids. Next, the constructs were digested with EcoRI. The resulting
double-digested L4 and H4 were then ligated into the blunt SmaI site and
EcoRI site of L5 and H1, respectively. Selected shRNA (shLuc1 and shApoB)
and U1i double (L4/L5 and H1/H4) constructs were further subcloned into a
pro-AAV vector that encodes CMV-eGFP, using SphI (for shRNA), and MunI
and SalI (for double U1i constructs) (Supplementary Figure 2). The resulting
AAV-shRNA/U1i plasmids are AH (shApoB/H1/H4), AL (shApoB/L4/L5),
LH (shLuc1/H1/H4), and LL (shLuc1/L4/L5). Reporter constructs that were
used are pRL-CMV-renilla (Promega), and ﬁreﬂy luciferase pGL4 (Promega)
under control of the CMV promoter or the liver-speciﬁc AAT promoter
in a pGEM-3Zf+ plasmid (Promega). Plasmid encoding AAT-secreted
alkaline phosphatase (AAT-SEAP) was made by BaseClear (Leiden,
The Netherlands).
AAV vector production
AAV serotype 1 vectors were produced by calcium phosphate-mediated
co-transfection in human embryonic kidney (HEK) 293 cells as described
previously.34 Viral batches were produced for AAV-shRNA/U1i constructs AH,
AL, LH, and LL and crude lysate was puriﬁed by afﬁnity chromatography,
diaﬁltrated in 5% PBS sucrose (v/w) by cross-ﬂow ﬁltration and further
concentrated using centricon tubes (YM-100; Millipore, Bedford, MA, USA).
The ﬁnal concentration of 5–10 1011 genome copies per ml was determined by
qPCR (Applied Biosystems, Foster City, CA, USA) using primers pr59 and pr60
(Supplementary Table 2), amplifying a 70-bp fragment from the CMV promoter
region. AAV-CMV-luciferase (AAV-Luc) was produced in insect cells through the
use of recombinant baculovirus technology, as described in Smith et al.35
Luciferase assay
The HEK293T cell line was maintained in Dulbecco’s modiﬁed Eagle’s medium
(DMEM; Invitrogen, Carlsbad, CA, USA) containing 10% fetal calf serum,
100Uml 1 penicillin, and 100Uml 1 streptomycin at 371C and 5% CO2.F o r
luciferase assays, approximately 2.5 104 HEK293T cells were seeded in 96-well
plates and transfected using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. Cells were co-transfected with 2.5ng CMV-ﬁreﬂy
luciferase plasmid and 0.5ng pRL-CMV-renilla luciferase plasmid, together
with a selection of shRNA (1–250ng), U1i (100–200ng), and shRNA/U1i
(25–250ng) constructs. The total amount of transfected DNA was kept
constant per experiment by adding vector control plasmid (pSuper, pGEM-
3Zf+, or pro-AAV plasmid). Two days after transfection, ﬁreﬂy and renilla
luciferase expression was assessed using a luminometer (Spectramax L; Mole-
cular Devices, Sunnyvale, CA, USA) according to the Dual-Luciferase Reporter
Assay System (Promega). Relative luciferase activity was calculated as the ratio
between ﬁreﬂy and renilla luciferase activities. To correct for between-session
variation in replicate experiments, the factor correction program was used.36
Statistical analysis was performed using one-way analysis of variance, with or
without repeated measures, and a Bonferroni post hoc comparison. A P-value
o0.05 was considered signiﬁcant.
In vivo transfection of murine liver using hydrodynamic tail vein
injection
All animal experiments were conducted according to the guidelines of the
local animal welfare committee. Six-to-eight-week-old female C57BL/6 mice
were anesthetized using intraperitoneal injection with fentanyl-ﬂuanisone-
midazolam (FFM) mix and hydrodynamically transfected via the tail vein with
plasmids encoding AAT-Luc (2mg), AAT-SEAP (0.5mg), shRNA (shApoB or
shLuc1) (10mg), and double U1i (H1/H4 or L4/L5) (40mg) in 1.5ml Ringer’s
solution (0.9% NaCl, 0.03% KCl, and 0.016% CaCl2). Two days after transfec-
tion, luciferase was measured in living mice in the Spectrum In Vivo Imaging
System (IVIS, Caliper Life Sciences, Hopkinton, MA, USA). Mice were
anesthetized with 2% isoﬂurane and injected intraperitoneally with 3mg
D-luciferin (Synchem, Felsberg, Germany) in 200ml PBS. Regions of interest
(ROIs) were traced over the positions of greatest signal intensity on the animal
and light intensity was quantiﬁed as photonss 1cm 2sr 1. At the same time
point, plasma was collected by retro-orbital bleed and secreted alkaline
phosphatase (SEAP) was measured using the chemiluminescent SEAP reporter
gene assay according to the manufacturer’s instructions (Roche Diagnostics
GmbH, Mannheim, Germany). Luciferase readings were normalized to SEAP
levels to adjust for transfection efﬁciency. Statistical analysis was performed
using one-way analysis of variance and a Bonferroni post hoc comparison.
A P-value o0.05 was considered signiﬁcant.
In vivo transduction of murine muscle using AAV
Six-to-eight-week-old female Balb/C mice were injected intramuscularly with a
mixture of AAV-Luc and AAV-shRNA/U1i (AAV-AH, AAV-AL, AAV-LH, or
AAV-LL). Gastrocnemic and adductor muscles were injected with 1 1010 gc
per limb AAV-Luc and 4.5 1010 gc per limb AAV-shRNA/U1i. Luciferase
expression in living mice was monitored in the IVIS at 1, 2, 3, 4, 6, and 8 weeks
post-transduction, as described above. Statistical analysis was performed using
one-way analysis of variance with repeated measures and a Bonferroni post hoc
comparison. A P-value o0.05 was considered signiﬁcant.
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